vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Ralliant Corp (RAL). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $529.1M, roughly 1.5× Ralliant Corp). Insulet Corporation runs the higher net margin — 13.0% vs 7.5%, a 5.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -0.5%). Ralliant Corp produced more free cash flow last quarter ($126.6M vs $48.2M).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
PODD vs RAL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $529.1M |
| Net Profit | $101.6M | $39.9M |
| Gross Margin | 72.6% | 50.8% |
| Operating Margin | 18.7% | 9.8% |
| Net Margin | 13.0% | 7.5% |
| Revenue YoY | 31.2% | -0.5% |
| Net Profit YoY | 0.9% | -56.1% |
| EPS (diluted) | $1.42 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | — | ||
| Q3 25 | $706.3M | $529.1M | ||
| Q2 25 | $649.1M | $503.3M | ||
| Q1 25 | $569.0M | — | ||
| Q4 24 | $597.5M | — | ||
| Q3 24 | $543.9M | $531.7M | ||
| Q2 24 | $488.5M | $533.7M | ||
| Q1 24 | $441.7M | — |
| Q4 25 | $101.6M | — | ||
| Q3 25 | $87.6M | $39.9M | ||
| Q2 25 | $22.5M | $47.6M | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $100.7M | — | ||
| Q3 24 | $77.5M | $90.9M | ||
| Q2 24 | $188.6M | $64.8M | ||
| Q1 24 | $51.5M | — |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | 50.8% | ||
| Q2 25 | 69.7% | 49.3% | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | 52.6% | ||
| Q2 24 | 67.7% | 51.5% | ||
| Q1 24 | 69.5% | — |
| Q4 25 | 18.7% | — | ||
| Q3 25 | 16.7% | 9.8% | ||
| Q2 25 | 18.7% | 11.7% | ||
| Q1 25 | 15.6% | — | ||
| Q4 24 | 18.3% | — | ||
| Q3 24 | 16.2% | 20.9% | ||
| Q2 24 | 11.2% | 19.7% | ||
| Q1 24 | 12.9% | — |
| Q4 25 | 13.0% | — | ||
| Q3 25 | 12.4% | 7.5% | ||
| Q2 25 | 3.5% | 9.5% | ||
| Q1 25 | 6.2% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 14.2% | 17.1% | ||
| Q2 24 | 38.6% | 12.1% | ||
| Q1 24 | 11.7% | — |
| Q4 25 | $1.42 | — | ||
| Q3 25 | $1.24 | $0.35 | ||
| Q2 25 | $0.32 | $0.42 | ||
| Q1 25 | $0.50 | — | ||
| Q4 24 | $1.38 | — | ||
| Q3 24 | $1.08 | $0.81 | ||
| Q2 24 | $2.59 | $0.57 | ||
| Q1 24 | $0.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $264.2M |
| Total DebtLower is stronger | $930.8M | $1.1B |
| Stockholders' EquityBook value | $1.5B | $3.0B |
| Total Assets | $3.2B | $5.3B |
| Debt / EquityLower = less leverage | 0.61× | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $264.2M | ||
| Q2 25 | — | $198.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | $1.1B | ||
| Q2 25 | $939.0M | $1.1B | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | $3.0B | ||
| Q2 25 | $1.5B | $3.0B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.1B | $4.0B | ||
| Q2 24 | $998.4M | $4.0B | ||
| Q1 24 | $790.7M | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | $5.3B | ||
| Q2 25 | $3.5B | $5.2B | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.0B | — | ||
| Q2 24 | $2.9B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | 0.39× | ||
| Q2 25 | 0.64× | 0.38× | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.72× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $138.6M |
| Free Cash FlowOCF − Capex | $48.2M | $126.6M |
| FCF MarginFCF / Revenue | 6.2% | 23.9% |
| Capex IntensityCapex / Revenue | 17.2% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.80× | 3.47× |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | — | ||
| Q3 25 | $125.7M | $138.6M | ||
| Q2 25 | $196.5M | — | ||
| Q1 25 | $63.8M | — | ||
| Q4 24 | $147.7M | — | ||
| Q3 24 | $98.5M | — | ||
| Q2 24 | $96.5M | — | ||
| Q1 24 | $87.6M | — |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $100.1M | $126.6M | ||
| Q2 25 | $177.9M | — | ||
| Q1 25 | $51.5M | — | ||
| Q4 24 | $94.1M | — | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $65.5M | — |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 14.2% | 23.9% | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 15.7% | — | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 17.2% | — | ||
| Q3 25 | 3.6% | 2.3% | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 4.6% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.43× | 3.47× | ||
| Q2 25 | 8.73× | — | ||
| Q1 25 | 1.80× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
